Myriad Genetics, Inc. (0K3W.L)
USD 7.95
(2.42%)
USD 7.95
(2.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 600.1 Million USD | -11.97% |
| 2021 | 681.7 Million USD | 4.35% |
| 2020 | 653.3 Million USD | 1.86% |
| 2019 | 641.4 Million USD | 0.0% |
| 2018 | 641.4 Million USD | 19.24% |
| 2017 | 537.9 Million USD | -2.34% |
| 2016 | 550.8 Million USD | 28.18% |
| 2015 | 429.7 Million USD | -2.67% |
| 2014 | 441.5 Million USD | 11.89% |
| 2013 | 394.57 Million USD | 29.14% |
| 2012 | 305.54 Million USD | 21.72% |
| 2011 | 251.02 Million USD | 27.04% |
| 2010 | 197.59 Million USD | 7.8% |
| 2009 | 183.28 Million USD | 16.89% |
| 2008 | 156.79 Million USD | -40.43% |
| 2007 | 263.2 Million USD | 51.23% |
| 2006 | 174.04 Million USD | 31.63% |
| 2005 | 132.22 Million USD | 28.59% |
| 2004 | 102.82 Million USD | 20.22% |
| 2003 | 85.53 Million USD | 8.11% |
| 2002 | 79.11 Million USD | 28.06% |
| 2001 | 61.77 Million USD | 21.38% |
| 2000 | 50.89 Million USD | 13.46% |
| 1999 | 44.85 Million USD | 18.67% |
| 1998 | 37.8 Million USD | -0.79% |
| 1997 | 38.1 Million USD | 27.42% |
| 1996 | 29.9 Million USD | 74.85% |
| 1995 | 17.1 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 174.2 Million USD | 2.53% |
| 2023 Q3 | 194.4 Million USD | -18.8% |
| 2023 Q2 | 239.4 Million USD | 37.43% |
| 2022 Q4 | 169.9 Million USD | 12.52% |
| 2022 Q3 | 151 Million USD | 2.44% |
| 2022 Q2 | 147.4 Million USD | 11.84% |
| 2022 Q1 | 131.8 Million USD | -16.64% |
| 2022 FY | 600.1 Million USD | -11.97% |
| 2021 Q4 | 158.1 Million USD | -20.55% |
| 2021 Q2 | 154.3 Million USD | -8.48% |
| 2021 Q1 | 168.6 Million USD | 11.58% |
| 2021 FY | 681.7 Million USD | 4.35% |
| 2021 Q3 | 199 Million USD | 28.97% |
| 2020 Q3 | 141.7 Million USD | 13.54% |
| 2020 FY | 653.3 Million USD | 1.86% |
| 2020 Q2 | 124.8 Million USD | -18.22% |
| 2020 Q1 | 152.6 Million USD | -1.17% |
| 2020 Q4 | 151.1 Million USD | 6.63% |
| 2019 Q1 | 162.1 Million USD | 2.86% |
| 2019 Q2 | 170.7 Million USD | 5.31% |
| 2019 Q3 | 156.8 Million USD | -8.14% |
| 2019 Q4 | 154.4 Million USD | -1.53% |
| 2019 FY | 641.4 Million USD | 0.0% |
| 2018 Q2 | 139.1 Million USD | 4.12% |
| 2018 Q4 | 157.6 Million USD | 4.37% |
| 2018 FY | 641.4 Million USD | 19.24% |
| 2018 Q1 | 133.6 Million USD | 1.06% |
| 2018 Q3 | 151 Million USD | 8.55% |
| 2017 Q1 | 139.7 Million USD | 0.58% |
| 2017 Q4 | 132.2 Million USD | -0.6% |
| 2017 FY | 537.9 Million USD | -2.34% |
| 2017 Q3 | 133 Million USD | -5.61% |
| 2017 Q2 | 140.9 Million USD | 0.86% |
| 2016 Q4 | 138.9 Million USD | 5.79% |
| 2016 Q2 | 110.8 Million USD | 2.88% |
| 2016 Q1 | 107.7 Million USD | 0.19% |
| 2016 FY | 550.8 Million USD | 28.18% |
| 2016 Q3 | 131.3 Million USD | 18.5% |
| 2015 Q3 | 103.7 Million USD | -10.76% |
| 2015 FY | 429.7 Million USD | -2.67% |
| 2015 Q1 | 107.95 Million USD | -2.04% |
| 2015 Q2 | 116.2 Million USD | 7.64% |
| 2015 Q4 | 107.5 Million USD | 3.66% |
| 2014 Q3 | 108.05 Million USD | 3.37% |
| 2014 Q4 | 110.19 Million USD | 1.99% |
| 2014 FY | 441.5 Million USD | 11.89% |
| 2014 Q1 | 101.02 Million USD | 6.42% |
| 2014 Q2 | 104.53 Million USD | 3.47% |
| 2013 Q2 | 86.12 Million USD | 10.11% |
| 2013 Q1 | 78.22 Million USD | 6.18% |
| 2013 FY | 394.57 Million USD | 29.14% |
| 2013 Q4 | 94.93 Million USD | 0.9% |
| 2013 Q3 | 94.08 Million USD | 9.24% |
| 2012 FY | 305.54 Million USD | 21.72% |
| 2012 Q1 | 66.45 Million USD | 8.53% |
| 2012 Q4 | 73.67 Million USD | 9.1% |
| 2012 Q3 | 67.52 Million USD | -1.74% |
| 2012 Q2 | 68.72 Million USD | 3.42% |
| 2011 Q2 | 53.11 Million USD | 7.48% |
| 2011 Q4 | 61.22 Million USD | 12.1% |
| 2011 FY | 251.02 Million USD | 27.04% |
| 2011 Q1 | 49.41 Million USD | -0.79% |
| 2011 Q3 | 54.61 Million USD | 2.84% |
| 2010 FY | 197.59 Million USD | 7.8% |
| 2010 Q3 | 45.25 Million USD | 0.46% |
| 2010 Q2 | 45.05 Million USD | -3.58% |
| 2010 Q1 | 46.72 Million USD | -0.93% |
| 2010 Q4 | 49.8 Million USD | 10.06% |
| 2009 Q1 | 53.94 Million USD | -2.89% |
| 2009 Q4 | 47.16 Million USD | 6.35% |
| 2009 Q3 | 44.34 Million USD | 1467.08% |
| 2009 Q2 | -3.24 Million USD | -106.01% |
| 2009 FY | 183.28 Million USD | 16.89% |
| 2008 Q1 | 61.31 Million USD | 6.11% |
| 2008 FY | 156.79 Million USD | -40.43% |
| 2008 Q4 | 55.55 Million USD | 9.9% |
| 2008 Q3 | 50.54 Million USD | -44.81% |
| 2008 Q2 | 91.59 Million USD | 49.37% |
| 2007 Q3 | 52.51 Million USD | 4.73% |
| 2007 Q2 | 50.14 Million USD | 18.02% |
| 2007 Q1 | 42.48 Million USD | 132.96% |
| 2007 FY | 263.2 Million USD | 51.23% |
| 2007 Q4 | 57.78 Million USD | 10.05% |
| 2006 Q2 | 37.94 Million USD | 10.76% |
| 2006 Q1 | 34.25 Million USD | 11.74% |
| 2006 FY | 174.04 Million USD | 31.63% |
| 2006 Q4 | 18.23 Million USD | -54.9% |
| 2006 Q3 | 40.43 Million USD | 6.58% |
| 2005 Q4 | 30.65 Million USD | 4.41% |
| 2005 FY | 132.22 Million USD | 28.59% |
| 2005 Q2 | 29.18 Million USD | 15.01% |
| 2005 Q1 | 25.37 Million USD | 0.75% |
| 2005 Q3 | 29.36 Million USD | 0.62% |
| 2004 Q2 | 22.15 Million USD | 4.47% |
| 2004 Q1 | 21.21 Million USD | 0.62% |
| 2004 Q3 | 23.08 Million USD | 4.19% |
| 2004 Q4 | 25.18 Million USD | 9.08% |
| 2004 FY | 102.82 Million USD | 20.22% |
| 2003 Q1 | 18.83 Million USD | -12.43% |
| 2003 Q2 | 20.1 Million USD | 6.71% |
| 2003 Q3 | 21.08 Million USD | 4.88% |
| 2003 FY | 85.53 Million USD | 8.11% |
| 2003 Q4 | 21.08 Million USD | -0.0% |
| 2002 Q4 | 21.51 Million USD | 15.28% |
| 2002 FY | 79.11 Million USD | 28.06% |
| 2002 Q3 | 18.66 Million USD | 0.61% |
| 2002 Q2 | 18.54 Million USD | 26.6% |
| 2002 Q1 | 14.65 Million USD | -0.28% |
| 2001 Q4 | 14.69 Million USD | 5.81% |
| 2001 FY | 61.77 Million USD | 21.38% |
| 2001 Q1 | 12.67 Million USD | -5.62% |
| 2001 Q2 | 12.05 Million USD | -4.9% |
| 2001 Q3 | 13.88 Million USD | 15.19% |
| 2000 FY | 50.89 Million USD | 13.46% |
| 2000 Q4 | 13.43 Million USD | 5.47% |
| 2000 Q1 | 12.45 Million USD | 20.87% |
| 2000 Q2 | 12.44 Million USD | -0.08% |
| 2000 Q3 | 12.73 Million USD | 2.36% |
| 1999 Q2 | 9.7 Million USD | 2.11% |
| 1999 Q1 | 9.5 Million USD | 0.0% |
| 1999 FY | 44.85 Million USD | 18.67% |
| 1999 Q4 | 10.3 Million USD | 6.19% |
| 1999 Q3 | 9.7 Million USD | 0.0% |
| 1998 Q4 | 9.5 Million USD | 3.26% |
| 1998 FY | 37.8 Million USD | -0.79% |
| 1998 Q1 | 9.6 Million USD | 10.34% |
| 1998 Q2 | 10.7 Million USD | 11.46% |
| 1998 Q3 | 9.2 Million USD | -14.02% |
| 1997 Q1 | 7.3 Million USD | -3.95% |
| 1997 Q2 | 8.5 Million USD | 16.44% |
| 1997 Q3 | 9.1 Million USD | 7.06% |
| 1997 FY | 38.1 Million USD | 27.42% |
| 1997 Q4 | 8.7 Million USD | -4.4% |
| 1996 Q3 | 6.4 Million USD | 20.75% |
| 1996 FY | 29.9 Million USD | 74.85% |
| 1996 Q1 | 5 Million USD | 38.89% |
| 1996 Q4 | 7.6 Million USD | 18.75% |
| 1996 Q2 | 5.3 Million USD | 6.0% |
| 1995 Q4 | 3.6 Million USD | 0.0% |
| 1995 FY | 17.1 Million USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 94.148% |
| Dynavax Technologies Corporation | 219.14 Million USD | -173.837% |
| Illumina, Inc. | 3.81 Billion USD | 84.262% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 70.77% |
| Biogen Inc. | 5.2 Billion USD | 88.47% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -33.062% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 44.914% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 55.901% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -13.438% |
| Waters Corporation | 943.51 Million USD | 36.398% |
| Perrigo Company plc | 1.52 Billion USD | 60.739% |
| uniQure N.V. | 285.08 Million USD | -110.498% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -46.793% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -40.325% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -117.67% |
| bluebird bio, Inc. | 240.23 Million USD | -149.8% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -321.232% |
| Imunon, Inc. | 21.03 Million USD | -2753.484% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 62.412% |
| Nektar Therapeutics | 190.9 Million USD | -214.348% |
| Editas Medicine, Inc. | 247.3 Million USD | -142.657% |
| Verastem, Inc. | 92.08 Million USD | -551.688% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 98.522% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -4214.274% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -397.36% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1243.497% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 65.635% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -162.419% |
| Evolus, Inc. | 189.75 Million USD | -216.243% |
| Adicet Bio, Inc. | 152.03 Million USD | -294.704% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -4842.756% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 78.684% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -120.709% |
| FibroGen, Inc. | 398.11 Million USD | -50.736% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 71.626% |
| OPKO Health, Inc. | 574.68 Million USD | -4.422% |
| Homology Medicines, Inc. | 9.87 Million USD | -5976.962% |
| Geron Corporation | 70.44 Million USD | -751.919% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 66.662% |
| Exelixis, Inc. | 1.58 Billion USD | 62.181% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -495.178% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -976.297% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -8.799% |
| Zoetis Inc. | 2.76 Billion USD | 78.297% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -25.976% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -1137.269% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 87.432% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1432.705% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 23.023% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -62.8% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -100.489% |
| Blueprint Medicines Corporation | 722.86 Million USD | 16.983% |
| Insmed Incorporated | 949.26 Million USD | 36.782% |
| TG Therapeutics, Inc. | 198.47 Million USD | -202.355% |
| Incyte Corporation | 1.19 Billion USD | 49.592% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 42.519% |